Aldo D’IMperio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aldo D’IMperio has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Peviani
University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy
1 shared publicationAlessandro Piccolo
University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy
1 shared publicationAndrea Crippa
University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy
1 shared publication- Cecilia Maria Esposito
Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Health Sciences, Florence University, Italy
1 shared publication Cecilia Spallarossa
University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy
1 shared publication- Daniel Stahl
King's College London
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 23 March 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 1-11
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials
Negative symptoms (avolition, anhedonia, asociality, blunted affect, and alogia) are among the most disabling features of schizophrenia spectrum disorders. In the absence of treatment consensus guidelines, this PRISMA-compliant meta-analysis (PROSPERO: CRD42024613967) evaluated efficacy and clinical significance of interventions targeting this dimension. Web of Science/PsycInfo databases were searched from inception to December 2024. Five categories (antipsychotics, other pharmacological agents, brain stimulation, psychosocial, and lifestyle interventions) were analyzed across short/middle/long follow-up times. Categories were divided into 27 subcategories (e.g., ‘other pharmacological agents’ divided in 14 subcategories including antidepressants, antibiotics, immunomodulators) regardless of follow-up, assessing evidence with GRADE criteria. The primary outcome was the change in negative symptom severity, measured with validated scales (PANSS/SANS/BPRS/CAINS/BNSS) as standardized mean differences (SMD). A clinically meaningful SMD threshold was estimated from the regression between SMD and one-point reductions on the Clinical Global Impression-Severity (CGI-S) scale. This study meta-analyzed 451 trials (n = 42566). The clinically meaningful threshold, obtained from 122 trials reporting CGI-S, was SMD ≥ 0.457. In 214 high-quality studies (n = 19746), 2 category-by-follow-up combinations and 16 subcategories showed significant improvements. Clinically meaningful SMDs for subcategories were antibiotics (0.95; CI: 0.18–1.71; moderate-GRADE), integrated psychosocial interventions (0.93; CI: 0.53–1.33; very-low-GRADE), antidepressants (0.76; CI: 0.33–1.19; moderate-GRADE), physical activity (0.68; CI: 0.39–0.96; very-low-GRADE), transcranial current stimulation (0.52; CI: 0.17–0.86; low-GRADE), and immunomodulators (0.47; CI: 0.26–0.67; high-GRADE), typically as adjuncts to antipsychotics. Heterogeneity was the main limitation. While selected interventions may yield meaningful improvements, more rigorous designs are needed to identify reliable, personalized and scalable treatment options.
- 23 March 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (8) , 1-11
Top Cited PapersOpen AccessInterventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials
Negative symptoms (avolition, anhedonia, asociality, blunted affect, and alogia) are among the most disabling features of schizophrenia spectrum disorders. In the absence of treatment consensus guidelines, this PRISMA-compliant meta-analysis (PROSPERO: CRD42024613967) evaluated efficacy and clinical significance of interventions targeting this dimension. Web of Science/PsycInfo databases were searched from inception to December 2024. Five categories (antipsychotics, other pharmacological agents, brain stimulation, psychosocial, and lifestyle interventions) were analyzed across short/middle/long follow-up times. Categories were divided into 27 subcategories (e.g., ‘other pharmacological agents’ divided in 14 subcategories including antidepressants, antibiotics, immunomodulators) regardless of follow-up, assessing evidence with GRADE criteria. The primary outcome was the change in negative symptom severity, measured with validated scales (PANSS/SANS/BPRS/CAINS/BNSS) as standardized mean differences (SMD). A clinically meaningful SMD threshold was estimated from the regression between SMD and one-point reductions on the Clinical Global Impression-Severity (CGI-S) scale. This study meta-analyzed 451 trials (n = 42566). The clinically meaningful threshold, obtained from 122 trials reporting CGI-S, was SMD ≥ 0.457. In 214 high-quality studies (n = 19746), 2 category-by-follow-up combinations and 16 subcategories showed significant improvements. Clinically meaningful SMDs for subcategories were antibiotics (0.95; CI: 0.18–1.71; moderate-GRADE), integrated psychosocial interventions (0.93; CI: 0.53–1.33; very-low-GRADE), antidepressants (0.76; CI: 0.33–1.19; moderate-GRADE), physical activity (0.68; CI: 0.39–0.96; very-low-GRADE), transcranial current stimulation (0.52; CI: 0.17–0.86; low-GRADE), and immunomodulators (0.47; CI: 0.26–0.67; high-GRADE), typically as adjuncts to antipsychotics. Heterogeneity was the main limitation. While selected interventions may yield meaningful improvements, more rigorous designs are needed to identify reliable, personalized and scalable treatment options.